Racial and sociodemographic disparities in the use of targeted therapies in advanced ovarian cancer patients with Medicare.
Anne KniselyChi-Fang WuAlexa KanbergsNuria AgustiKirsten A JorgensenAlexander MelamedSharon H GiordanoJose Alejandro Rauh-HainRoni Nitecki WilkePublished in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2024)
Sociodemographic and racial disparities exist in receipt of PARPi and bevacizumab among patients with advanced ovarian cancer insured by Medicare. As targeted therapies become more commonly used, a widening disparity gap is likely.